Skip to main content
Jason Fangusaro, MD, Pediatric Hematology & Oncology, Atlanta, GA

Jason Ronald Fangusaro MD

Pediatric Neuro-Oncology


Director of Developmental Therapeutics Professor of Pediatrics Emory University School of Medicine, Aflac Cancer Center and the Children's Healthcare of Atlanta

Join to view full profile
  • 2220 N Druid Hills RdAtlanta, GA 30329

  • Phone+1 404-785-7000

  • Fax+1 404-325-6166

Dr. Fangusaro is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Jason Fangusaro is a Pediatric Neuro-Oncologist. He currently is the Director of Developmental Therapeutics at CHOA/Emory. Published in several high-impact journals, he has contributed to the field with numerous brain tumor clinical trials. He serves as the Co-Director of both RAPNO and the International Pediatric Low-grade Glioma Coalition, and he is the Vice Chair of the COG CNS committee.

Education & Training

  • Children's Hospital of Los Angeles
    Children's Hospital of Los AngelesFellowship, Pediatric Neuro-Oncology, 2005 - 2006
  • Nationwide Children's Hospital/Ohio State University
    Nationwide Children's Hospital/Ohio State UniversityFellowship, Pediatric Hematology/Oncology, 2002 - 2005
  • Advocate Health Care/Advocate Children's Hospital (Park Ridge)
    Advocate Health Care/Advocate Children's Hospital (Park Ridge)Residency, Pediatrics, 1999 - 2002
  • Loyola University Chicago Stritch School of Medicine
    Loyola University Chicago Stritch School of MedicineClass of 1999
  • Loyola University Chicago
    Loyola University ChicagoB.A., Theatre Arts, 1991 - 1995

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2018 - 2027
  • IL State Medical License
    IL State Medical License 2001 - 2020
  • CA State Medical License
    CA State Medical License 2005 - 2007
  • OH State Medical License
    OH State Medical License 2001 - 2007
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • World's Top 2% Scientists Stanford University, 2023
  • Regional Top Doctor Castle Connolly, 2014
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Prospective Feasibility and Safety of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma  
    Gupta N, Goumnerova LC, Manley P, Chi SN, Neuberg D, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Ge..., Neuro Oncol, 1/5/2018
  • Phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC)  
    Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S..., Neuro Oncol, 1/28/2017
  • Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival  
    Marinoff AE, Ma C, Guo D, Snuderl M, Wright KD, Manley PE, Al- Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, London WB, Kieran MW, Chi SN, Fang..., 1/21/2017

Books/Book Chapters

Abstracts/Posters

  • Outcomes of a Phase 2 trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System (CNS) Non-Germinomatous Germ Cell Tumors NGGCT): a C...
    Fangusaro J, Wu S, MacDonald S, Murphy E, Shaw D, Bartels U, Khatua S, Boyett J, Williams-Hughes C, Souweidane M, Lu H, Morris D, Panigrahy A, Onar-Thomas A, Fouladi M..., Neuro-Oncology, 1/1/2018
  • A Phase II and Re-treatment Study of Selumetinib in Children with Recurrent/Progressive LGG: a Pediatric Brain Tumor Consortium Study
    Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn L, Pollack IF, Qaddoumi I, Fisher PG, Dhall G, Baxter P, Kreissman..., Neuro-Oncology, 1/1/2018
  • A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG: A Pediatric Brain Tumor Consortium Study
    Fangusaro J,� Onar-Thomas A,� Young-Poussaint T,�Wu S, Ligon AH, Lindeman NI, Banerjee A,�Packer R,�Kilburn LB,�Pollack I,�Jakacki R,�Qaddoumi IA, Fisher PG, Dhall G,�..., Journal of Clini Oncology, 1/1/2017

Lectures

  • A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Targeting MAPK in Pediatric Oncology 
    Chicago, IL - 1/1/2018
  • A Phase II and Re-treatment Study of Selumetinib in Children with Recurrent/Progressive LGG: a Pediatric Brain Tumor Consortium Study 
    Denver, CO - 1/1/2018

Other

  • Selumetinib in children with recurrent or refractory low-grade glioma 
    ASCO Interview
    1/1/2017
  • Pediatric Brain and Spinal Cord Tumors 
    Pediatric Neuro-Oncology: Ask the Experts
    http://www.youtube.com/watch?v=LZ3ibm8-ZWo
    1/1/2013

Press Mentions

  • Evolving Treatment Approaches in Pediatric Low-Grade Glioma
    Evolving Treatment Approaches in Pediatric Low-Grade GliomaApril 8th, 2025
  • Contents
    ContentsFebruary 11th, 2021
  • Pediatric Brain Tumor Consortium Adds Members: Dana-Farber, the Hospital for Sick Children, Univ. Of Florida & Nationwide Children’s Hospital
    Pediatric Brain Tumor Consortium Adds Members: Dana-Farber, the Hospital for Sick Children, Univ. Of Florida & Nationwide Children’s HospitalSeptember 2nd, 2020

Grant Support

  • R50NIH/NCI2026–2031

Committees

  • Co-leader, International Coalition on Pediatric LGG 2020 - Present
  • Co-Chair, RAPNO 2020 - Present
  • Member, COG CNS Steering Committee 2017 - Present
  • Vice-Chair, PBTC Executice Committee 2016 - Present
  • Member, International CNS GCT Committee 2013 - Present

Professional Memberships

Other Languages

  • Spanish

Industry Relationships

  • Pediatric "Unbranded" Educational Speaker's Bureau, DAY ONEEducational Talks that are focused on Pediatric Low-Grade Glioma (Unbranded)2021 - Present
  • PEDIATRIC ADVISORY BOARD, ASTRA ZENECA/ALEXION2020 - 2022
  • Pediatric Advisory Board, Celgene2016 - 2020

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: